English
Pharmacological prevention of altitude illness, so a few words about Acetazolamide
Kinga Kocur
Oskar Fogiel
Dominika Mularska
Jan Machalica
Katarzyna Camlet
Abstract
High-altitude illness is a condition occurring in individuals at high altitudes (above 2500 meters above sea level) resulting from inadequate acclimatization to the unique environment. Initially, the illness manifests as a set of nonspecific symptoms of acute mountain sickness (AMS). Rapid ascent to altitudes above 4000 meters can lead to severe complications, such as high-altitude cerebral edema (HACE) or high-altitude pulmonary edema (HAPE). With appropriate prevention measures, gradual ascent, and the use of medications such as acetazolamide, the risk of developing AMS can be significantly reduced. The mechanism of action of acetazolamide involves increased excretion of bicarbonates by the kidneys, leading to acidification of the blood (a decrease in blood pH). This process stimulates the respiratory center, increasing minute ventilation and improving oxygenation at high altitudes. Clinical studies have demonstrated that using acetazolamide at doses of 125 mg twice daily is effective in preventing AMS. Acetazolamide is well-tolerated, although it may cause side effects such as paresthesia, taste disturbances, or mild diuretic effects. Its use can significantly enhance the body's ability to adapt to high altitudes. In life-threatening conditions such as HAPE and HACE, the treatment primarily relies on other methods. Due to the increasing prevalence of travel to high-altitude regions, physicians and rescue workers are encountering this issue more frequently. The aim of this study is to compile current knowledge on the use of acetazolamide in altitude sickness.
Keywords:
acetazolamide, altitude illness, acute mountain sickness, HAPE, HACEMost read articles by the same author(s)
- Katarzyna Camlet, Kinga Kocur, Mateusz Ziomek, Anna Ziobro, Jakub Jurek, Anna Lis, Paulina Lis, Wojciech Kaźmierski, Is an acute overdose of zolpidem fatal? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Anna Lis, Paulina Lis, Wojciech Kaźmierski, Kinga Kocur, Katarzyna Camlet, Jakub Jurek, Mateusz Ziomek, Anna Ziobro, Sodium bicarbonate - known medication, new prospects? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Paulina Lis, Anna Lis, Wojciech Kaźmierski, Jakub Jurek, Mateusz Ziomek, Kinga Kocur, Anna Ziobro, Katarzyna Camlet, Inclisiran - a new solution for the prevention and treatment of atherosclerotic cardiovascular disease , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Wojciech Kaźmierski, Jakub Jurek, Paulina Lis, Anna Lis, Anna Ziobro, Mateusz Ziomek, Katarzyna Camlet, Kinga Kocur, Sodium-glucose cotransporter2 inhibitors in heart failure , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Kinga Kocur, Katarzyna Camlet, Anna Ziobro, Mateusz Ziomek, Wojciech Kaźmierski, Paulina Lis, Jakub Jurek, Anna Lis, Renaissance of Ketamine , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Dominika Mularska, Oskar Fogiel, Kinga Kocur, Małgorzata Rak, Natalia Pawlas, Insulin to the rescue: a review of recent reports on insulin treatment in emergencies and poisonings , Prospects in Pharmaceutical Sciences: Vol. 23 No. 3 (2025)
Similar Articles
- Natalia Cichoń, Dominika Lach, Joanna Saluk-Bijak, Michał Bijak, ANTICOAGULANT THERAPY IN ACUTE CORONARY SYNDROMES AND ISCHEMIC STROKE , Prospects in Pharmaceutical Sciences: Vol. 15 No. 5 (2017)
- Natalia Cichoń, Dominika Lach, Michał Bijak Bijak, Paulina Rzeźnicka, Joanna Saluk, SIMILARITIES AND DIFFERENCES IN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROMES AND ISCHEMIC STROKE , Prospects in Pharmaceutical Sciences: Vol. 14 No. 4 (2016)
- Michał Dacka, Mateusz Sobczyk , Paulina Dąbrowska , Kamila Giżewska , Michał Żuber , Role of calcitonin gene-related peptide (CGRP) receptor antagonist in acute and preventive treatment of migraine , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Dominika Mularska, Oskar Fogiel, Kinga Kocur, Małgorzata Rak, Natalia Pawlas, Insulin to the rescue: a review of recent reports on insulin treatment in emergencies and poisonings , Prospects in Pharmaceutical Sciences: Vol. 23 No. 3 (2025)
- Grzegorz Ślifirski, Tomasz Słowiński, Jacek Stefanowicz, NOVEL TRENDS IN ANTIPSYCHOTIC DRUG DEVELOPMENT , Prospects in Pharmaceutical Sciences: Vol. 13 No. 4 (2015)
- Katarzyna Czuba, Magdalena Mazurkiewicz, Kamil Kamiński, Filip Różewski, Dorota Skrajnowska, Andrzej Tokarz, BIOTERRORISM – THREAT, PREVENTIVE ACTIONS, INTERNATIONAL LAW , Prospects in Pharmaceutical Sciences: Vol. 9 No. 2 (2011)
- Dominika Winiarz, Kamila Domańska, Kinga Paluch, Dorota Dorota Skrajnowska, PROBIOTICS AND HEALTH - TODAY AND TOMORROW , Prospects in Pharmaceutical Sciences: Vol. 15 No. 10 (2017)
- Katarzyna Camlet, Kinga Kocur, Mateusz Ziomek, Anna Ziobro, Jakub Jurek, Anna Lis, Paulina Lis, Wojciech Kaźmierski, Is an acute overdose of zolpidem fatal? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Anna Lis, Paulina Lis, Wojciech Kaźmierski, Kinga Kocur, Katarzyna Camlet, Jakub Jurek, Mateusz Ziomek, Anna Ziobro, Sodium bicarbonate - known medication, new prospects? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Kinga Grużewska-Piotrowska, Agnieszka Grużewska, Medication overuse headache as a consequence of taking painkillers – a review of current literature , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
You may also start an advanced similarity search for this article.
Details
References
Statistics
Authors
Citation rules
Cited by / Share
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.